BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked
15 Luglio, 2020
Second-Quarter 2020 Business Performance Preannouncement
15 Luglio, 2020
CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®
27 Maggio, 2020
First-Quarter 2020 Business Review
24 Marzo, 2020
bioMérieux – 2019 Financial Results
14 Gennaio, 2020
bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance
14 Gennaio, 2020
bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology affiliate, has submitted to the Food and Drug Administration for 510(k) clearance of the BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. The BIOFIRE® BCID2 Panel includes several additional pathogens, an expanded list of antimicrobial resistance genes, and many revised targets compared to the existing BIOFIRE® BCID Panel.d about 9,800.